Impact of the anticancer drug nt157 on tyrosine kinase signaling networks

Shih-Ping Su, Efrat Flashner-Abramson, Shoshana Klein, Mor Gal, Rachel S. Lee, Jianmin Wu, Alexander Levitzki, Roger J. Daly

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The small-molecule drug NT157 has demonstrated promising efficacy in preclinical models of a number of different cancer types, reflecting activity against both cancer cells and the tumor microenvironment. Two known mechanisms of action are degradation of insulin receptor substrates (IRS)-1/2 and reduced Stat3 activation, although it is possible that others exist. To interrogate the effects of this drug on cell signaling pathways in an unbiased manner, we have undertaken mass spectrometry–based global tyrosine phosphorylation profiling of NT157-trea-ted A375 melanoma cells. Bioinformatic analysis of the resulting dataset resolved 5 different clusters of tyrosine-phosphorylated peptides that differed in the directionality and timing of response to drug treatment over time. The receptor tyrosine kinase AXL exhibited a rapid decrease in phosphorylation in response to drug treatment, followed by proteasome-dependent degradation, identifying an additional potential target for NT157 action. However, NT157 treatment also resulted in increased activation of p38 MAPK a and g, as well as the JNKs and specific Src family kinases. Importantly, cotreatment with the p38 MAPK inhibitor SB203580 attenuated the antiproliferative effect of NT157, while synergistic inhibition of cell proliferation was observed when NT157 was combined with a Src inhibitor. These findings provide novel insights into NT157 action on cancer cells and highlight how globally profiling the impact of a specific drug on cellular signaling networks can identify effective combination treatments.

Original languageEnglish
Pages (from-to)931-942
Number of pages12
JournalMolecular Cancer Therapeutics
Volume17
Issue number5
DOIs
Publication statusPublished - 1 May 2018

Cite this

Su, Shih-Ping ; Flashner-Abramson, Efrat ; Klein, Shoshana ; Gal, Mor ; Lee, Rachel S. ; Wu, Jianmin ; Levitzki, Alexander ; Daly, Roger J. / Impact of the anticancer drug nt157 on tyrosine kinase signaling networks. In: Molecular Cancer Therapeutics. 2018 ; Vol. 17, No. 5. pp. 931-942.
@article{07617b802a53431e9b26057b02d49fbc,
title = "Impact of the anticancer drug nt157 on tyrosine kinase signaling networks",
abstract = "The small-molecule drug NT157 has demonstrated promising efficacy in preclinical models of a number of different cancer types, reflecting activity against both cancer cells and the tumor microenvironment. Two known mechanisms of action are degradation of insulin receptor substrates (IRS)-1/2 and reduced Stat3 activation, although it is possible that others exist. To interrogate the effects of this drug on cell signaling pathways in an unbiased manner, we have undertaken mass spectrometry–based global tyrosine phosphorylation profiling of NT157-trea-ted A375 melanoma cells. Bioinformatic analysis of the resulting dataset resolved 5 different clusters of tyrosine-phosphorylated peptides that differed in the directionality and timing of response to drug treatment over time. The receptor tyrosine kinase AXL exhibited a rapid decrease in phosphorylation in response to drug treatment, followed by proteasome-dependent degradation, identifying an additional potential target for NT157 action. However, NT157 treatment also resulted in increased activation of p38 MAPK a and g, as well as the JNKs and specific Src family kinases. Importantly, cotreatment with the p38 MAPK inhibitor SB203580 attenuated the antiproliferative effect of NT157, while synergistic inhibition of cell proliferation was observed when NT157 was combined with a Src inhibitor. These findings provide novel insights into NT157 action on cancer cells and highlight how globally profiling the impact of a specific drug on cellular signaling networks can identify effective combination treatments.",
author = "Shih-Ping Su and Efrat Flashner-Abramson and Shoshana Klein and Mor Gal and Lee, {Rachel S.} and Jianmin Wu and Alexander Levitzki and Daly, {Roger J.}",
year = "2018",
month = "5",
day = "1",
doi = "10.1158/1535-7163.MCT-17-0377",
language = "English",
volume = "17",
pages = "931--942",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research",
number = "5",

}

Impact of the anticancer drug nt157 on tyrosine kinase signaling networks. / Su, Shih-Ping; Flashner-Abramson, Efrat; Klein, Shoshana; Gal, Mor; Lee, Rachel S.; Wu, Jianmin; Levitzki, Alexander; Daly, Roger J.

In: Molecular Cancer Therapeutics, Vol. 17, No. 5, 01.05.2018, p. 931-942.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Impact of the anticancer drug nt157 on tyrosine kinase signaling networks

AU - Su, Shih-Ping

AU - Flashner-Abramson, Efrat

AU - Klein, Shoshana

AU - Gal, Mor

AU - Lee, Rachel S.

AU - Wu, Jianmin

AU - Levitzki, Alexander

AU - Daly, Roger J.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - The small-molecule drug NT157 has demonstrated promising efficacy in preclinical models of a number of different cancer types, reflecting activity against both cancer cells and the tumor microenvironment. Two known mechanisms of action are degradation of insulin receptor substrates (IRS)-1/2 and reduced Stat3 activation, although it is possible that others exist. To interrogate the effects of this drug on cell signaling pathways in an unbiased manner, we have undertaken mass spectrometry–based global tyrosine phosphorylation profiling of NT157-trea-ted A375 melanoma cells. Bioinformatic analysis of the resulting dataset resolved 5 different clusters of tyrosine-phosphorylated peptides that differed in the directionality and timing of response to drug treatment over time. The receptor tyrosine kinase AXL exhibited a rapid decrease in phosphorylation in response to drug treatment, followed by proteasome-dependent degradation, identifying an additional potential target for NT157 action. However, NT157 treatment also resulted in increased activation of p38 MAPK a and g, as well as the JNKs and specific Src family kinases. Importantly, cotreatment with the p38 MAPK inhibitor SB203580 attenuated the antiproliferative effect of NT157, while synergistic inhibition of cell proliferation was observed when NT157 was combined with a Src inhibitor. These findings provide novel insights into NT157 action on cancer cells and highlight how globally profiling the impact of a specific drug on cellular signaling networks can identify effective combination treatments.

AB - The small-molecule drug NT157 has demonstrated promising efficacy in preclinical models of a number of different cancer types, reflecting activity against both cancer cells and the tumor microenvironment. Two known mechanisms of action are degradation of insulin receptor substrates (IRS)-1/2 and reduced Stat3 activation, although it is possible that others exist. To interrogate the effects of this drug on cell signaling pathways in an unbiased manner, we have undertaken mass spectrometry–based global tyrosine phosphorylation profiling of NT157-trea-ted A375 melanoma cells. Bioinformatic analysis of the resulting dataset resolved 5 different clusters of tyrosine-phosphorylated peptides that differed in the directionality and timing of response to drug treatment over time. The receptor tyrosine kinase AXL exhibited a rapid decrease in phosphorylation in response to drug treatment, followed by proteasome-dependent degradation, identifying an additional potential target for NT157 action. However, NT157 treatment also resulted in increased activation of p38 MAPK a and g, as well as the JNKs and specific Src family kinases. Importantly, cotreatment with the p38 MAPK inhibitor SB203580 attenuated the antiproliferative effect of NT157, while synergistic inhibition of cell proliferation was observed when NT157 was combined with a Src inhibitor. These findings provide novel insights into NT157 action on cancer cells and highlight how globally profiling the impact of a specific drug on cellular signaling networks can identify effective combination treatments.

UR - http://www.scopus.com/inward/record.url?scp=85047802393&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-17-0377

DO - 10.1158/1535-7163.MCT-17-0377

M3 - Article

VL - 17

SP - 931

EP - 942

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 5

ER -